Cardiovascular issues with oral contraceptives: Evidenced-based medicine

International Journal of Fertility and Women's Medicine

Volumn 45, Issue 2, 2000, Pages 166-174

  Burkman, Ronald ^a,b  

^a BAYSTATE MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Myocardial infarction; Oral contraceptives; Stroke; Venous thromboembolism

Indexed keywords

ESTROGEN; ORAL CONTRACEPTIVE AGENT;

BLOOD CLOTTING FACTOR 5 DEFICIENCY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CIGARETTE SMOKING; DOSE RESPONSE; EVIDENCE BASED MEDICINE; HEART INFARCTION; HYPERTENSION; MIGRAINE; OBESITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOEMBOLISM; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGE DISTRIBUTION; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; CONTRACEPTIVES, ORAL; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INCIDENCE; MYOCARDIAL INFARCTION; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; UNITED STATES; VENOUS THROMBOSIS;

EID: 0033868771     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Consensus conference on combination oral contraceptives and cardiovascular disease. Fertil Steril 71:1S-6S, 1999.
2. Lewis MA: The epidemiology of oral contraceptive use: a critical review of the studies on oral contraceptives and the health of young women. Am J Obstet Gynecol 179:1086-1097, 1998.
3. Stadel BV: Oral contraceptives and cardiovascular disease (second of two parts). N Engl J Med 305:672-677, 1981.
4. Stadel BV: Oral contraceptives and cardiovascular disease (first of two parts). N Engl J Med 305:612-618, 1981.
5. Gerstman BB, Piper JM, Tomita DK, et al: Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease [see comments]. Am J Epidemiol 133:32-37, 1991.
6. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception [see comments]. Lancet 346:1575-1582, 1995.
7. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, et al: Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen [see comments]. Lancet 346:1593-1596, 1995.
8. Spitzer WO, Lewis MA, Heinemann LA, et al: Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women [see comments]. Br Med J 312:83-88, 1996.
9. Farmer RD, Lawrenson RA, Thompson CR, et al: Population-based study of risk of venous thromboembolism associated with various oral contraceptives [see comments]. Lancet 349:83-88, 1997.
10. Group WS: Cardiovascular Disease and Steroid Hormone Contraception, Geneva, World Health Organization, 1998.
11. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception [see comments]. Lancet 346:1582-1588, 1995.
12. Farmer RDT, Preston TD: The risk of venous thromboembolism associated with low oestrogen oral contraceptives. J Obstet Gynecol 15:195-200, 1995.
13. Jick H, Jick SS, Gurewich V, et al: Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components [see comments]. Lancet 346:1589-1593, 1995.
14. Jamin C, de Mouzon J: Selective prescribing of third generation oral contraceptives (OCs). Contraception 54:55-56, 1996.
15. Lidegaard O: Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. Br Med J 306:956-963, 1993.
16. Lidegaard O: Oral contraceptives and venous thromboembolism: an epidemiological review. Eur J Contracept Reprod Health Care 1:13-20, 1996.
17. Lidegaard O, Milsom I: Oral contraceptives and thrombotic diseases: impact of new epidemiological studies [editorial] [see comments]. Contraception 53:135-139, 1996.
18. Bloemenkamp KW, Rosendaal FR, Buller HR, et al: Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med 159:65-70, 1999.
19. Lewis MA, Heinemann LA, MacRae KD, et al: The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women [see comments] [published erratum appears in Contraception 1996 Aug;54(2):121]. Contraception 54:5-13, 1996.
20. Dahlback B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C [see comments]. Proc Natl Acad Sci USA 90:1004-1008, 1993.
21. Price DT, Ridker PM: Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective [see comments]. Ann Intern Med 127:895-903, 1997.
22. Vandenbroucke JP, van der Meer FJ, Helmerhorst FM, et al: Factor V Leiden: should we screen oral contraceptive users and pregnant women? [see comments]. Br Med J 313:1127-1130, 1996.
23. Winkler UH: Blood coagulation and oral contraceptives. A critical review. Contraception 57:203-209, 1998.
24. Vandenbroucke JP, Koster T, Briet E, et al: Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation [see comments]. Lancet 344:1453-1457, 1994.
25. Schambeck CM, Schwender S, Haubitz I, et al: Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives? Thromb Haemost 78:1480-1483, 1997.
26. Guyatt GH, Sackett DL, Sinclair JC, et al: Users' guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group [published erratum appears in JAMA 1996 Apr 24;275(16):1232]. JAMA 274:1800-1804, 1995.
27. Grimes DA: Introducing evidence-based medicine into a department of obstetrics and gynecology [see comments]. Obstet Gynecol 86:451-457, 1995.
28. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 348:498-505, 1996.
29. Hannaford PC, Croft PR, Kay CR: Oral contraception and stroke. Evidence from the Royal College of General Practitioners' Oral Contraception Study [see comments]. Stroke 25:935-942, 1994.
30. Heinemann LA, Lewis MA, Thorogood M, et al: Case-control study of oral contraceptives and risk of thromboembolic stroke: results from International Study on Oral Contraceptives and Health of Young Women. Br Med J 315:1502-1504, 1997.
31. Petitti DB, Sidney S, Bernstein A, et al: Stroke in users of low-dose oral contraceptives [see comments]. N Engl J Med 335:8-15, 1996.
32. Porter JB, Hunter JR, Jick H, Stergachis A: Oral contraceptives and nonfatal vascular disease. Obstet Gynecol 66:1-4, 1985.
33. Schwartz SM, Siscovick DS, Longstreth WT, Jr, et al: Use of low-dose oral contraceptives and stroke in young women. Ann Intern Med 127:596-603, 1997.
34. Schwartz SM, Petitti DB, Siscovick DS, et al: Stroke and use of low-dose oral contraceptives in young women: a pooled analysis of two US studies. Stroke 29:2277-2284, 1998.
35. Thorogood M, Mann J, Murphy M, et al: Fatal stroke and use of oral contraceptives: findings from a case-control study. Am J Epidemiol 136:35-45, 1992.
36. Vessey MP, Lawless M, Yeates D: Oral contraceptives and stroke: findings in a large prospective study. Br Med J (Clin Res Ed) 289:530-531, 1984.
37. Tzourio C, Tehindrazanarivelo A, Iglesias S, et al: Case-control study of migraine and risk of ischaemic stroke in young women. Br Med J 310:830-833, 1995.
38. Chang CL, Donaghy M, Poulter N: Migraine and stroke in young women: case-control study. The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception [see comments]. Br Med J 318:13-18, 1999.
39. Sidney S, Petitti DB, Quesenberry CP, Jr, et al: Myocardial infarction in users of low-dose oral contraceptives. Obstet Gynecol 88:939-944, 1996.
40. Sidney S, Siscovick DS, Petitti DB, et al. Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies. Circulation 98:1058-1063, 1998.
41. Lewis MA, Heinemann LA, Spitzer WO, et al: The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception 56:129-140, 1997.
42. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet 349:1202-1209, 1997.
43. D'Avanzo B, La Vecchia C, Negri E, et al: Oral contraceptive use and risk of myocardial infarction: an Italian case-control study. J Epidemiol Commun Health 48:324-325, 1994.
44. Rosenberg L, Palmer JR, Lesko SM, et al: Oral contraceptive use and the risk of myocardial infarction. Am J Epidemiol 131:1009-1016, 1990.
45. Stampfer MJ, Willett WC, Colditz GA, et al: A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med 319:1313-1317, 1988.
46. Croft P, Hannaford P: Risk factors for acute myocardial infarction in women [letter]. Br Med J 298:674, 1989.